Binding of -dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific

By Kilbourn M.   Lee L.   Borght T.V.   Jewett D.   Frey K.  

European Journal of Pharmacology, Vol. 278, Iss. 3, 1995-05 ,pp. : 249-252

Elsevier

Access to resources Recommend Favorite

The vesicular monoamine transporter is not regulated by dopaminergic drug treatments

By Borght T.V.   Kilbourn M.   Desmond T.   Kuhl D.   Frey K.  

European Journal of Pharmacology, Vol. 294, Iss. 2, 1995-12 ,pp. : 577-583

Elsevier

Access to resources Recommend Favorite

The Neuroprotective Role of Vesicular Monoamine Transporter 2 in Neurodegenerative Diseases

By  

Medicinal Chemistry, Vol. 11, Iss. 2, 2015-01 ,pp. : 104-108

Bentham Science Publishers

Access to resources Recommend Favorite

Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function

By Fleckenstein A.E.   Haughey H.M.   Metzger R.R.   Kokoshka J.M.   Riddle E.L.   Hanson J.E.   Gibb J.W.   Hanson G.R.  

European Journal of Pharmacology, Vol. 382, Iss. 1, 1999-10 ,pp. : 45-49

Elsevier

Access to resources Recommend Favorite

In vivo binding of (+)- -[ 3 H]dihydrotetrabenazine to the vesicular monoamine transporter of rat brain: bolus vs. equilibrium studies

By Kilbourn M.   Sherman P.  

European Journal of Pharmacology, Vol. 331, Iss. 2, 1997-07 ,pp. : 161-168

Elsevier

Access to resources Recommend Favorite